Comments
GVK Biosciences has extended its Clinical Biomarker Database (GOBIOM) licence to the Biomarker Qualification Group of the US Food and Drug Administration (USFDA). “The GOBIOM database, which has the latest information on all the biomarkers reported in various clinical and preclinical studies, will be of enormous use to USFDA in its Biomarker Qualification Process,'' the Hyderabad-based company said in a release.
The GOBIOM database is a comprehensive collection of all the clinically evaluated, exploratory and preclinical biomarkers associated with different therapeutic areas reported in global clinical trials, clinical and preclinical studies. It contains information on 12,000 biomarkers. “The collaboration with the USFDA helped GVK BIO in developing the safety biomarker content in GOBIOM,” Mr Sreeni Devidas, Vice-President, Sales & Marketing, Informatics, GVK Bio, said. Biomarker analysis tools were integrated into the database such that the user can make comparative analysis between biomarkers of their interest, he added
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.